ABSTRACT Arylsulfatase A polypeptides were examined in cultured fibroblasts from a patient with juvenile metachromatic leukodystrophy and three patients with the adult form of the disease, with the aid of metabolic labeling and immunoprecipitation. The mutant cells were severely deficient in the arylsulfatase polypeptides. The apparent rate of synthesis, however, as estimated from the secretion of polypeptides or activity by cells incubated in the presence of 10 mM NH4Cl was 20-50% of control. In the absence of NH4CI, the mutant enzyme was rapidly degraded upon transport into lysosomes. In the presence of inhibitors of thiol proteinases arylsulfatase A polypeptides were partially protected from degradation, and the catalytic activity of arylsulfatase A was increased. In addition, the treatment partially corrected the capacity of the cells to degrade cerebroside sulfates. Inhibitors of thiol proteinases may be of therapeutic value in variants of metachromatic leukodystrophy, in which an unstable arylsulfatase A is synthesized.
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Metachromatic leukodystrophy (MLD) comprises several genetic diseases characterized by an intralysosomal storage of cerebroside sulfates, the natural substrates of the lysosomal enzyme arylsulfatase A. Progressive neurological degeneration is the prominent clinical feature in MLD, which is subdivided into the more common late infantile forms and the less common juvenile and adult forms. Each form is deficient in arylsulfatase A and appears to be genetically distinct (for review see refs. 1 and 2). In rare cases presenting clinically as the juvenile form, arylsulfatase A is normal, but there is a deficiency in its activator protein (3) . Arylsulfatase A is one of several sulfatases missing in multiple sulfatase deficiency (1) . The primary defect in this disease is not known.
Lysosomal enzymes are synthesized as larger precursors and subsequently processed to smaller forms (4) . Two allelic precursors of arylsulfatase A with apparent Mrs of 62,000 and 59,000 are synthesized in cultured human skin fibroblasts. These precursors are processed to mature forms, which are smaller by a Mr of about 1,500 (5, 6) . Both absence and presence of arylsulfatase A polypeptides were found in fibroblasts from patients with late infantile MLD (5, 7) . In the present study we have examined the synthesis and processing of arylsulfatase A in fibroblasts of patients with the juvenile and adult forms of MLD (8, 9 (1) , the residual arylsulfatase A activity in the mutant cells was not, or only to small extent (less than 0.15 milliunits/mg of cell protein), precipitable with antiserum. The cells were maintained in culture as described (13) .
Labeling of Cells. Confluent cultures in 25-cm2 flasks were washed twice with 5 ml of serum-free medium (ref. 14 ; as formulated in the catalogue of GIBCO), with added antibiotics but free of methionine, and were incubated with 5 ml of this medium for 1 hr. For labeling the serum-free medium, 2 ml was supplemented with 0.1 ml of dialyzed fetal calf serum (GIBCO) that had been incubated at pH 10. 4 (15) . The secretions were precipitated with 2.5 g of (NH4)2SO4. The precipitate was dissolved in 1 ml of H20 and dialyzed overnight against two 100-ml portions of Eagle's minimal essential medium. After dialysis 0.25 ml of fetal calf Abbreviation: MLD, metachromatic leukodystrophy.
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Proc. Natl. Acad. Sci. USA 80 (1983) 6067 serum was added, and the volume was adjusted to 5 ml with culture medium. Confluent cultures in 75-cm2 flasks were incubated for 16-24 hr with the medium containing the labeled secretions (10-30 X 106cpm). Preincubation with inhibitors was performed as described above.
Immunoprecipitation of Lysosomal Enzymes. Preparation of extracts of cells and medium (15) ; immunoprecipitation of arylsulfatase A (5), cathepsin D, and B-hexosaminidase (15) ; polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate; and fluorography (15) were performed as described. In experiments with inhibitors, the extracts of cells and medium were prepared in buffers containing the inhibitors. The amount of radioactivity in the polypeptides visualized by fluorography was determined by liquid scintillation counting (16) .
Secretion of Arylsulfatase A Activity. Confluent cultures in 75-cm2 flasks were incubated for 72 hr in 15 ml of the serumfree medium, with added antibiotics, 10 mM NH4Cl, and 1% of the dialyzed and pH-inactivated fetal calf serum. The medium was concentrated 100-fold by ultrafiltration, mixed with 1 part of 50 mM Tris HCI (pH 7.4), anct stored at -20'C. The cells were harvested for protein determination (17) . Activity of arylsulfatase A (18) and ,3-hexosaminidase (19) were determined as described. One unit of enzyme activity is the amount of enzyme hydrolyzing 1 gmol of substrate per min.
Utilization of Cerebroside Sulfates.
[3H]Cerebroside sulfates (180 Ci/mol) were kindly provided by G. Schwarzmann (Bonn). Fibroblasts in 25-cm2 flasks were incubated with 4 ml of medium with or without 100 ,uM leupeptin. After 6 days the medium (with or without inhibitors) was renewed, and 8 nmol of3H-labeled cerebroside sulfates were added. After incubation for 5 days, cells were processed for quantitation and separation of cell-associated3H-labeled lipids as described (20, 21) .
RESULTS
Metabolic Labeling of Arylsulfatase A. As observed previously (5-7) in normal fibroblasts, a larger precursor polypeptide of arylsulfatase A was synthesized, and nearly 10% of it was secreted. The remainder was processed to a smaller form intracellularly. Besides the control, cell lines representing late infantile, juvenile, and adult forms of MLD were investigated. In all of the mutants, the labeling of arylsulfatase A was severely impaired. As shown in Fig. 1 for representative cell lines of the three forms of MLD, no radioactivity was found in arylsulfatase A polypeptides intracellularly. However, the medium of juvenile and adult MLD fibroblasts contained about half of the normal amount of arylsulfatase A precursor. Similar results were obtained in several experiments in which the cells were labeled for 6-24 hr. Occasionally, however, in juvenile and adult MLD fibroblasts, radioactive arylsulfatase A was found in the cells (<10% of control). One of several possible explanations for these observations is that arylsulfatase A is synthesized and secreted in juvenile and adult MLD fibroblasts as in controls but is degraded rapidly when sequestered into lysosomes.
To test this hypothesis, fibroblasts were labeled in the presence of 10 mM NH4Cl. Under these conditions <10% of the newly synthesized arylsulfatase A is delivered into the lysosomes, and the remainder is secreted into the medium (5, 6). The amount of labeled arylsulfatase A polypeptides in secretions of juvenile and adult MLD fibroblasts was 20-50% of control (Fig. 2) , calculated for each cell line as the ratio of radioactivity in arylsulfatase A to radioactivity in cathepsin D, a Iysosomal enzyme that is not affected in MLD. After a lag phase of 2.5 hr, the secretion was linear and leveled off after 12 24 hr, the media were removed, and cells were either harvested or subjected to a chase for 24 hr or 48 hr as indicated above the lanes. Arylsulfatase A and (3hexosaminidase were immunoprecipitated in sequence. The migration of precursor and mature forms of arylsulfatase A and 3hexos-aminidase are indicated. The minor 3-hexosaminidase polypeptides are fragments of the mature 13-chain (14) .
The activity of arylsulfatase A in the secretions of normal and late infantile MLD fibroblasts was 1.14 (mean of three cell lines) and 0.05 milliunits per mg of cell protein. -Hexosaminidase activity secreted in normal and MLD fibroblasts varied between 92 and 105 milliunits per mg of cell protein.
Further evidence for the synthesis of short-lived arylsulfatase A polypeptides in adult MLD fibroblasts -was obtained in a pulse (6 hr)-chase (48 hr) labeling experiment. In controls the radioactivity in arylsulfatase A decreased by <5% and in adult MLD fibroblasts (cell lines 0. and K.) decreased by 75-80% during the chase period.
Endocytosis of Arylsulfatase A. The previous experiments established the synthesis of arylsulfatase A in juvenile and adult MLD fibroblasts. To assess the postulated rapid lysosomal breakdown of the mutant arylsulfatase A, arylsulfatase A secreted by normal or adult MLD fibroblasts was added to the medium of adult MLD fibroblasts. Arylsulfatase A secreted by normal fibroblasts was efficiently endocytosed (Fig. 3) . About 40% of the added arylsulfatase A was recovered within the cells as the mature form after 24 hr and was largely preserved during the following chase of up to 48 hr. In contrast, arylsulfatase A produced in adult MLD fibroblasts was barely recovered in the recipient cells. In a few experiments (e.g., in the experiment shown in Fig. 4) , some endocytosed arylsulfatase A was detectable. Other lysosomal enzymes were internalized to a similar extent from secretions of either normal or MLD fibroblasts (shown for /3-hexosaminidase in Fig. 3) .
Stabilization of Arylsulfatase A Polypeptides by Proteinase Inhibitors. When the endocytosis experiment described above was performed with secretions of juvenile (not shown) or adult MLD fibroblasts in the presence of leupeptin, antipain, or chymostatin, arylsulfatase A was recovered from the homogenates of the recipient cells (Fig. 4) . These inhibitors are known to inhibit thiol proteinases. In contrast, pepstatin, an inhibitor of cathepsin D-like aspartyl proteinases, was without protective effect. Excessive degradation of endocytosed mutant arylsuilfatase A and partial inhibition thereof in treated cells was seen with adult MLD (Fig. 4 Left) and with normal (Fig. 4 Trif gatonm fuor emm at arylsulfatase A activity wase det e-n 0.63 and 0.72 milliunits/mg of cell protein.
apparent effect on the stability of the mutant arvisulfatase A (Fig. 4 Right). The protection of arvlsulfatase A from excessive degradation in the juvenile and adult MNILD fibroblasts by inhibitors of thiol proteinases also was observed for the endogenous enzymes when mutant cells were labeled in the presence of the inhibitors (Fig. 5) More importantly, the arylsulfatase A recovered in fibroblasts treated with leupeptin appears to be localized in the lvsosomes and to degrade cerebroside sulfates, the natural sub-strates of arylsulfatase A. Indirect evidence for the lysosomal localization was provided by the observation that inhibitors of thiol proteinases caused an accumulation of the mature forms of arylsulfatase A. The conversion of the precursors to the mature forms of endogenous arylsulfatase A is thought to occur only after their delivery into lysosomes (5) . Further evidence for the lysosomal localization of the arylsulfatase A spared from degradation was provided by means of a cerebroside sulfate loading test. In this test the capacity of fibroblasts to degrade the internalized cerebroside sulfates in the lysosomes and to utilize subsequently the lipid components for synthesis of endogenous lipids is measured. In the presence of leupeptin, the degradation and utilization of cerebroside sulfates in adult MLD fibroblasts was restored to about half normal values.
In several other lysosomal storage diseases, the enzyme deficiency results from excessive degradation. In multiple sulfatase deficiency, the activities of all known sulfatases, including those located Pytralosontml. are decr.esd. At !eat2 hdeficiencies in arylsulfatase A (16) and arylsulfatase B (F. Steckel, unpublished data) result from accelerated degradation. The primary defect rendering these two sulfatases unstable is unknown. In combined /3-galactosidase and neuraminidase deficiency, a protein normally protecting both enzymes from excessive degradation is missing (22) . In the late-onset form of Pompe disease (a-glucosidase deficiency), the mutant a-glucosidase appears to be subjected to degradation on its way to the lysosomes (23) .
The protection by proteinase inhibitors of aberrant lysosomal enzymes from rapid degradation, resulting in elevation of the residual enzyme activity, may be of therapeutic benefit for patients. The toxicity of thiol proteinase inhibitors appears to be low or even negligible in various animals (24) . Further studies on mutations causing the instability of lysosomal enzymes may reveal the structural rules for the stability of lysosomal enzymes in the lysosomal milieu.
